News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunogen Inc
(NQ:
IMGN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunogen Inc
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Immunogen's Earnings: A Preview
April 27, 2023
Via
Benzinga
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
April 24, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results
April 13, 2023
From
ImmunoGen Inc.
Via
Business Wire
Could This Move Make Vertex's Next Blockbuster Even Bigger?
April 12, 2023
Vertex is showing it can branch out beyond its cystic fibrosis specialty.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
April 07, 2023
Via
Benzinga
Earnings Scheduled For March 1, 2023
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
Analyst Ratings for Immunogen
January 23, 2023
Via
Benzinga
Analyst Ratings for Immunogen
December 30, 2022
Via
Benzinga
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
April 06, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
March 25, 2023
From
ImmunoGen, Inc.
Via
Business Wire
6 Analysts Have This to Say About Immunogen
December 30, 2022
Via
Benzinga
What 6 Analyst Ratings Have To Say About Immunogen
December 30, 2022
Via
Benzinga
Why Shares of MacroGenics Jumped Thursday
March 09, 2023
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy.
Via
The Motley Fool
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Allows Vertex Pharma Use Its Technology For Conditioning Agents For Use With Gene Editing
March 01, 2023
Via
Benzinga
ImmunoGen Reports Recent Progress and 2022 Financial Results
March 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
March 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
February 22, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results
February 15, 2023
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
February 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
January 04, 2023
From
ImmunoGen, Inc.
Via
Business Wire
What You Missed On Wall Street On Friday
December 31, 2022
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold.
Via
Talk Markets
Futu Holdings, UP Fintech Holding And Some Other Big Stocks Moving Lower On Friday
December 30, 2022
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Friday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Ardelyx To Rally 160%? Here Are 10 Other Price Target Changes For Friday
December 30, 2022
Citigroup raised Ardelyx, Inc. (NASDAQ: ARDX) price target from $6 to $7. Citigroup analyst Yigal Nochomovitz maintained a Buy rating on the stock. Ardelyx shares rose 9.4% to $2.7685 on Friday.
Via
Benzinga
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
December 28, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen's Newly Approved Ovarian Cancer Drug Listed As Preferred Regime
December 28, 2022
The National Comprehensive Cancer Network (NCCN) released new guidelines for ovarian cancer treatment, which include ImmunoGen Inc's (NASDAQ: IMGN) Elahere (mirvetuximab soravtansine-gynx) as a...
Via
Benzinga
ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
December 27, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
December 17, 2022
Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will...
Via
Talk Markets
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.